Caris Life Sciences, Inc. (CAI): Long-Term Debt
$378.45M
As of 2025-12-31
$392.69M
As of 2026-06-30
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $378.45M | +1.4% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $373.14M | n/a | 2026-03-03, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $378.45M | +1.4% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $1.50B | +31.6% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $10.06M | +0.3% |
| RadNet, Inc. (RDNT) | 2025-12-31 | $1.09B | +7.2% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $57.23M | +11.2% |
| Biodesix Inc (BDSX) | 2025-12-31 | $50.01M | +24.9% |
| Exagen Inc. (XGN) | 2025-12-31 | $22.91M | +13.1% |
| Quest Diagnostics Inc (DGX) | 2025-12-31 | $5.67B | -8.8% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $17.40M | -14.8% |
Compare CAI, GH, CSTL, RDNT side by side · Screen every company in Services-Medical Laboratories ↗